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Summary Antiprogestins have been largely utilized in
reproductive medicine, yet their repositioning for oncologic
use is rapidly emerging. In this study we investigated the
molecular mediators of the anti-ovarian cancer activity of
the structurally related antiprogestins RU-38486, ORG-
31710 and CDB-2914. We studied the responses of wt p53
OV2008 and p53 null SK-OV-3 cells to varying doses of
RU-38486, ORG-31710 and CDB-2914. The steroids
inhibited the growth of both cell lines with a potency of
RU-38486 > ORG-31710 > CDB-2914, and were cytostatic
at lower doses but lethal at higher concentrations.
Antiprogestin-induced lethality associated with morpho-
logical features of apoptosis, hypodiploid DNA content,
DNA fragmentation, and cleavage of executer caspase
substrate PARP. Cell death ensued despite RU-38486
caused transient up-regulation of anti-apoptotic Bcl-2,
ORG-31710 induced transient up-regulation of inhibitor
of apoptosis XIAP, and CDB-2914 up-regulated both
XIAP and Bcl-2. The antiprogestins induced accumula-
tion of Cdk inhibitors p21
cip1 and p27
kip1 and increased
association of p21
cip1 and p27
kip1 with Cdk-2. They also
promoted nuclear localization of p21
cip1 and p27
kip1,
reduced the nuclear abundances of Cdk-2 and cyclin E,
and blocked the activity of Cdk-2 in both nucleus and
cytoplasm. The cytotoxic potency of the antiprogestins
correlated with the magnitude of the inhibition of Cdk-2
activity, ranging from G1 cell cycle arrest towards cell
death. Our results suggest that, as a consequence of their
cytostatic and lethal effects, antiprogestin steroids of well-
known contraceptive properties emerge as attractive new
agents to be repositioned for ovarian cancer therapeutics.
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Introduction
The first antiprogestin synthesized was RU-38486 (a.k.a.
“RU-486”), now named mifepristone [1]. RU-38486 has
been mainly used as blocker of progesterone receptors in
the uterus, where it increases the sensitivity to myometrial
contractions induced by prostaglandin analogues, leading to
early termination of pregnancy [2]. Yet RU-38486 is useful
for other reproductive indications, such as oral contracep-
tion, menstrual cycle regulation and emergency contracep-
tion [3]. More recently, RU-38486 emerged to treat
endocrine-related diseases such as uterine leiomyoma and
endometriosis [4].
The potential use of RU-38486 in oncology is promising.
In non-reproductive tissues, RU-38486 inhibited the growth
ofgastric cancercelllines [5] and of meningioma cells [6]. In
reproductive tissues, RU-38486 blocked proliferation and
killed benign and malignant endometrial cancer cells [7]. In
prostate cancer, RU-38486 blocked growth of androgen-
sensitive and androgen-insensitive LNCaP cells in vivo and
in vitro [8]. In breast cancer, RU-38486 inhibited the growth
of T-47D cells [9], and in MCF-7 cells it had an additive
lethal effect when combined with antiestrogen tamoxifen
[10]. In MCF-7 cells, RU-38486 had a synergistic lethal
interaction with the Chk1 inhibitor 7-hydroxystaurosporine
(UCN-01) [11] or with 4-hydroxytamoxifen [12]. Also, RU-
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hydroxytamoxifen [13] and was lethal to progesterone
receptor- and estrogen receptor-negative MDA-MB-231 cells
[14]. In p53/BRCA1-deficient mice, RU-38486 prevented the
formation of breast tumors [15]. RU-38486 also inhibited the
growth of cervical adenocarcinoma cells in vitro and in vivo
[16].
The action of antiprogestins in ovarian cancer has
received limited attention. First in 1996 it was revealed
that RU-38486 arrested OVCAR-3 and A2780 cells at the
G1 phase of the cell cycle [17]. More recently we
demonstrated the efficacy of RU-38486 as a single agent
in an in vivo preclinical setting and found that its growth
inhibitory effect was associated with inhibition of DNA
synthesis, G1 cell cycle arrest, and down-regulation of
transcription factor E2F1 needed for S phase progression
[18]. We also demonstrated that RU-38486 inhibits the
growth of ovarian cancer cells regardless of p53 genetic
makeup and platinum sensitivity [19]. Finally, we have
shown that cytostatic concentrations of RU-38486 added
after courses of lethal platinum-based chemotherapy pre-
vent repopulation of remnant cancer cells escaping and
surviving the insult of the platinating agent [20].
ORG-31710 and CDB-2914 are two members of a
family of selective progesterone receptor modulators with
a similar structure to RU-38486, as they all contain a
dimethylaminophenyl substitution at the 11β-position that
confers antiprogestin activity [2, 4, 21] (Fig. 1). ORG-
31710 and CDB-2914, however, were designed aiming to
decrease the antagonistic effect of RU-38486 on the
glucocorticoid receptor by substitutions made at the 17α
side chain [4]. Limited information is available regarding
the growth inhibition and oncologic value of these two
antiprogestins. Studies in rats show that ORG-31710 and
CDB-2914 were effective inr e d u c i n gt h eg r o w t ho f
established DMBA-induced breast tumors by increasing
apoptosis and blocking cell proliferation [22, 23]. In
cultured human uterine leiomyoma cells, CDB-2914
inhibited cell proliferation down-regulating PCNA expres-
sion, and inducing apoptosis up-regulating PARP expres-
sion and reducing Bcl-2 abundance [24]. Further a recent
randomized controlled clinical trial reported that CDB-2914
significantly reduced leiomyoma growth [25]. ORG-31710,
on the other hand, increased apoptosis in human periovu-
latory granulosa cells [26].
Based on our previous findings on the in vitro and in
vivo growth inhibitory effect of RU-38486 in ovarian
cancer cells, the goal of this study was to investigate the
molecular mediators of the anti-ovarian cancer activity of
RU-38486 and of the two structurally related antiproges-
tins, ORG-31710 and CDB-2914 (Ulipristal). We report
that RU-38486, ORG-31710 and CDB-2914 all are cyto-
static at lower concentrations, up-regulating and promoting
nuclear localization of the cyclin dependent kinase (Cdk)
inhibitors p27
kip1 and p21
cip1, reducing nuclear abundances
of Cdk-2 and cyclin E, and reducing the activity of Cdk-2.
At higher concentrations the three antiprogestins blunted
the activity of Cdk-2 leading to the death of the ovarian
cancer cells, which was associated with morphological
features of apoptosis, hypodiploid DNA content, fragmen-
tation of the DNA, and cleavage of the executer caspase
substrate PARP.
Materials and methods
Cell culture and drugs
The human ovarian carcinoma cell line OV2008 was
obtained in 2003 from Dr. Howell (University of California,
San Diego) and was maintained in RPMI 1640 (Mediatech,
Herndon, VA) supplemented with 5% heat inactivated fetal
bovine serum (Atlanta Biologicals, Lawrencenville, GA),
10mMHEPES(Mediatech),4 mML-glutamine(Mediatech),
1 mM sodium pyruvate (Mediatech), 1 x non-essential
amino acids (Mediatech), 100 IU penicillin (Mediatech),
and 100 μg/ml streptomycin (Mediatech). SK-OV-3
ovarian cancer cells were obtained in 2003 at passage
23 from the American Tissue Culture Collection (Manassas,
VA) and were routinely maintained in RPMI 1640
(Mediatech) supplemented with 5% fetal bovine serum
(Atlanta Biologicals), 10 mM HEPES (Mediatech),
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(Sigma Chemical Company, St. Louis, MO), 1 mM
sodium pyruvate (Mediatech), 1 x non-essential amino
acids (Mediatech), 100 IU penicillin (Mediatech),
100 μg/ml streptomycin (Mediatech), and 0.01 mg/ml
human insulin (Roche, Indianapolis, IN). Both cell lines
were cultured at 37°C in a humidified atmosphere in the
presence of 5% CO2. Treatment of the cells with
RU-38486 (Sigma), ORG-31710 (generously provided by
N.V. Organon, Oss, The Netherlands), or CDB-2914
(kindly provided by HRA Pharma, Paris, France) were
done from 20 mM stock solutions in DMSO; the maximal
concentration of DMSO in medium was 0.2% (v/v).
Cell proliferation and viability
Triplicate cultures were trypsinized, pelleted by centrifuga-
tion at 500g for 5 min, and washed with PBS. The cells
were resuspended in ViaCount reagent (Guava Technolo-
gies, Hayward, CA) and studied using the Guava ViaCount
application in the Guava EasyCyte Mini microcapillary
cytometer (Guava Technologies) as we previously reported
[20]. When indicated, the proliferation IC50 values were
determined using software designed to study drug interac-
tion that calculates the median effective dose, Dm, which is
analogous to the IC50 (Calcusyn, Biosoft, Cambridge, UK).
Cell cycle analysis
After treatment, cells were trypsinized, pelleted by centri-
fugation at 500g for 5 min, washed with PBS, and fixed
with 4% paraformaldehyde. Cells were once again washed
with PBS and pelleted by centrifugation at 500g for 5 min.
Then approximately 100,000–200,000 cells were resus-
pended in 200 μl of cell cycle buffer [3.8 mM sodium
citrate (Sigma), 7 U/ml RNase A (Sigma), 0.1% (v/v)
Triton X-100 (Sigma), and 0.05 mg/ml propidium iodide
(Sigma)] at a concentration of 500–1000 cells/μl. Cells
were analyzed for the capacity of their DNA to bind
propidium iodide utilizing the Guava EasyCyte Mini
microcapillary cytometer and the cell cycle application of
the CytoSoft 4.1 software (Guava Technologies).
Immunoblot analysis
Cells were scraped, pelleted, washed twice with PBS, and
lysed by the addition of two volumes of NP-40 lysis buffer
containing 50 mM Tris–HCl (pH 7.5), 150 mM NaCl, 0.5%
NP-40 (Sigma), 50 mM sodium fluoride (Sigma), 1 mM
PMSF (Sigma), 2 μg/ml pepstatin (Sigma), 2 μg/ml
leupeptin (Sigma), 2 μg/ml aprotinin (Sigma), and 1 mM
orthovanadate (Sigma). Lysates were centrifuged at 16,000g
for 15 min at 4°C, and the supernatant was considered the
whole cell extract, which was assayed for protein content
using the bicinchoninic acid method (BCA; Pierce, Rockford,
IL). The whole cell extracts were appropriately diluted in
3 x concentrated electrophoresis sample buffer, boiled for
10 min, and stored at −80°C until electrophoresed.
Equivalent amounts of proteins (50 μg) per point were
loaded in 12% (w/v) acrylamide gels, subjected to SDS-
PAGE and transferred to PVDF membranes. The blots
were blocked in 5% (v/v) non-fat milk in TBS containing
0.1% (v/v) Tween 20 (T). Blots were probed overnight
with the appropriate dilution of each of the primary
antibodies. The membranes were washed 3×5 min in TBS-T
and incubated with 1: 10,000 dilution of peroxidase-
conjugate secondary antibody (#111-035-003; Jackson
ImmunoResearchLaboratories,WestGrove,PA)for30minat
room temperature. The blots were again washed, developed
by chemiluminescence, and exposed to radiographic film.
Blots were stripped and reprobed with an antibody directed
against the ubiquitous proteins glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), or β-actin, to control for protein
loading. Primary antibodies for the following proteins
were used at the indicated dilutions. Cyclin E (clone HE12;
0.5 μg/ml), and p21
cip1 (clone 6B6; 2 μg/ml) were from BD
Pharmigen (San Diego, CA); p27
kip1 (clone 57; 1: 2,000)
was from BD Transduction Laboratories (San Diego, CA);
XIAP (#2042; 1:500), poly (ADP-ribose) polymerase
(PARP; #9592; 1:1,000) and caspase-3 (#9662; 1:1,000)
were from Cell Signaling Technology (Danvers, MA); Cdk-2
(M2; 1:1,000) and Bcl-2 (100; 1:1000) were from Santa
Cruz Biotechnology (Santa Cruz, CA); GAPDH (ab9485;
1:10,000) was from Abcam Inc. (Cambridge, MA); β-actin
(clone AC-15; 1:20,000) was from Sigma.
Cdk-2 immunoprecipitation and histone H1 kinase assay
An aliquot (100 μg of protein) from each NP-40 cell lysate
was incubated overnight at 4°C with constant rotation in
1 ml of NP-40 lysis buffer containing 1 μg polyclonal
rabbit antibody to Cdk-2 (M2; Santa Cruz Biotechnology).
Immunocomplexes associated with Cdk-2 were collected
after incubation for 2 h with protein A/G PLUS-Agarose
beads (Santa Cruz Biotechnology). The immune-complexes
were washed twice with kinase buffer [50 mM HEPES
(pH 7.2), 10 mM MgCl2, 1 mM DTT, 10 mM β-
glycerophosphate, and 1 mM sodium fluoride]. Subse-
quently, the beads were resuspended in 30 μlo fk i n a s e
buffer containing 2 μg of histone H1 (Upstate Cell
Signaling Solutions, Lake Placid, NY), 5 μMA T P
(Upstate), and 5 μCi of [γ
32P] ATP (MP Biomedicals,
Irvine, CA). The reaction mixtures were incubated at 30°C
for 30 min, the reaction was terminated with 30 μlo f2x
electrophoresis sample buffer, boiled, and separated on
12% SDS/polyacrylamide gels. Gels were stained with
Invest New Drugs (2012) 30:967–980 969Coomassie Blue (Sigma) to visualize the histone H1
bands, dried, and autoradiographed.
Subcellular fractionation
Upon treatment with vehicle or antiprogestins, cells were
washed in PBS, scrapped, pelleted, and resuspended in low
salt lysis buffer [10 mM HEPES (pH 7.9), 10 mM KCl,
1.5 mM MgCl2, 1 mM DTT, 1 mM PMSF, 1 mM sodium
orthovanadate, 2 μg/ml aprotinin, 2 μg/ml leupeptin, and
2 μg/ml pepstatin], incubated on ice for 15 min and
homogenized with a hand pestle. The lysates where then
centrifuged for 10 min at 800 x g at 4°C. The pellet
represents the nuclear fraction. The supernatant was further
centrifuged for 10 min at 16,000 x g at 4°C to remove any
contaminant nuclei. The new supernatant was considered
the cytosolic fraction. The crude nuclear fraction was
washed twice with low salt lysis buffer, pelleted down for
5 min at 800 x g, resuspended in NP-40 lysis buffer
(described above), and rocked for 1 h at 4°C. The
suspension was centrifuged at 16,000 x g for 20 min to
remove debris, and the supernatant was considered the
nuclear fraction. The protein concentrations of both factions
were determined as described above. Fifty μg of each of the
protein fractions were subjected to SDS-PAGE, transferred
to PVDF membranes, and immunoblotted with antibodies
against p27
kip1, p21
cip1, Cdk-2, cyclin E, and GAPDH or
β-actin for loading control.
4′, 6-Diamidino-2-phenylindole dihydochloride (DAPI)
staining and phase contrast microscopy
OV2008 or SK-OV-3 cells cultured on 6-well plates were
exposed to either vehicle (DMSO), or 20 or 40 μM
antiprogestins for 96 h. After treatment, detached cells
were collected, centrifuged at 500g for 5 min, fixed and
resuspended in 100% methanol, adhered to a microscope
slide, and stained for 10 min with DAPI (Molecular Probes,
Eugene, OR). Nuclear morphology was observed and
photographed using a Zeiss Axiovert M200 inverted
fluorescence microscope (Carl Zeiss, Thornwood, NY).
Cells that remained adherent to the original chamber slide
were also fixed in 100% methanol, stained with DAPI and
photographed. All cell preparations were simultaneously
photographed using a phase contrast objective.
DNA fragmentation
Floating and adherent cells were pelleted and digested
overnight at 50°C in a buffer composed of 100 mM NaCl,
10 mM Tris HCl (pH 8.0), 25 mM EDTA (pH 8.0), 0.5%
SDS and 0.1 mg/ml proteinase K (Life Technologies,
Rockville, MD). The genomic DNA was extracted from
the digested cells with phenol/chloroform/isoamyl alcohol
(25:24:1, v/v/v), precipitated, and digested for 60 min at
37°C with 1 μg/ml ribonuclease (deoxyribonuclease-
free; Roche). After extraction and precipitation, an
equal amount of DNA for each sample (2 μg) was
separated by electrophoresis on a 2.5% agarose gel,
impregnated with SYBR Gold nucleic acid gel stain
(Molecular Probes), examined using an ultraviolet
transilluminator, and photographed with the Amersham
Typhoon Fluorescence imaging system (Amersham Bio-
sciences Corp., Piscataway, NJ). A 100 bp DNA ladder
(Promega, Madison, WI) was utilized for determining
the size of the fragments of DNA.
Results
Antiprogestins inhibit, in a dose-related manner, the growth
of p53 wild type and p53 mutant ovarian cancer cells,
eliciting concentration dependent cytostatic and lethal
effects
To explore whether RU-38486, ORG-31710 or CDB-2914
can inhibit the growth of ovarian cancer cells of different
genetic backgrounds, we studied the response to the
antiprogestins in OV2008 cells that express wild type p53
[27], and SK-OV-3 cells that carry a deletion of a single
nucleotide as a consequence of which no p53 mRNA
transcripts are expressed [28]. The two cell lines were
exposed to vehicle or increasing concentrations of the
antiprogestins for 72 h. At the end of the experiment, the
cells were evaluated and analyzed by microcapillary
cytometry for cell number, cell viability, and cell cycle
distribution. Results shown in Fig. 2a and d illustrate that
both cell lines were growth inhibited by the three
antiprogestins in a dose-related manner. In OV2008 cells,
RU-38486 had a growth inhibition concentration 50% or
IC50 lower than that of ORG-31710 or CDB-2914
(Fig. 1b). In SK-OV-3 cells, RU-38486 and ORG-31710
had similar growth inhibition potency which was, however,
higher than that of CDB-2914 (Fig. 2e). Neither RU-38486
nor ORG-31710 or CDB-2914 showed lethality towards the
cells at the 20 μM concentration. At the concentration of
40 μM, however, the three antiprogestins reduced the
viability of both cell lines, with the effect being more
prominent in OV2008 cells (Fig. 2c) than in SK-OV-3 cells
(Fig. 2f).
The cytostatic effect of the 20 μM dose of the three
antiprogestins was reinforced by the fact that after 72 or
96 h treatment the cells remained attached to the culture
plate, although in a reduced number when compared to
vehicle-treated controls (Fig. S1). It is interesting to note
that at cytostatic concentrations the antiprogestins not only
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of the cells. More evident in SK-OV-3 than in OV2008
cells, the cells acquired an elongated morphology. Con-
versely, more evident in OV2008 than in SK-OV-3 cells,
scattered cells with multi-nucleation and multi-vacuolation
were evident (Fig. S1).
When the cell cycle traverse of OV2008 was studied by
microcytometric analysis of propidium iodide-labeled DNA
particles, it was evident that 20 μM antiprogestins had a
cytostatic but not a lethal effect. This was indicated by the
lack of cellular particles containing hypodiploid (Sub-G1)
DNA content, the increased proportion of cells transiting
the G0-G1 phase of the cell cycle, which was accompanied
by a reduction in the proportion of cells allocated to the S
phase, and no apparent changes in the proportion of cells
transiting G2/M (Fig. 3a). When the antiprogestins were
used at the 40 μM concentration, there was an evident
increase in the percentage of hypodiploid-DNA containing
cellular particles that was more evident for RU-38486 and
ORG-31710 when compared to CDB-1914. The lethality of
high concentration antiprogestins was further evidenced for
RU-38486 and ORG-31710 by the reduction in the
percentage of cells transiting G0-G1, which was not seen
in CDB-2914 that still showed G0-G1 block (Fig. 3a).
To study the dynamics of the cell cycle upon antipro-
gestin challenge, cell cycle distribution was assessed in
OV2008 cells after 12, 24, or 48 h treatment (Fig. 3b)o ri n
SK-OV-3 cells after 24, 48, 72, or 96 h treatment (Fig. 4).
To link the kinetics of the cell cycle with the growth
inhibitory and lethal effects of the compounds, for these
time-course studies we utilized the lethal 40 μM concen-
tration. In OV2008 cells RU-38486 caused, after 24 h
treatment, Sub-G1 DNA accumulation without any increase
in G1, suggesting the cells are likely dying without
arresting (Fig. 3b, upper panels, and lower left panel);
however, the same concentration of ORG-31710 and CDB-
2914 caused G1 arrest after 12 and 24 h treatment (Fig. 3b,
upper panels). ORG-31710 showed Sub-G1 accumulation
beginning at 48 h exposure with a parallel decline in G1,
whereas CDB-2914 still showed G1 arrest 48 h after
treatment (Fig. 3b, lower left panel). The three compounds
abrogated growth as indicated by the stagnant cell number
Fig. 2 Effect of antiprogestins on the growth of p53 wild type
(OV2008) and p53 null (SK-OV-3) ovarian cancer cells. OV2008 a-c
or SK-OV-3 d-f cells were cultured in the presence of the indicated
concentrations of RU-38486, ORG-31710, or CDB-2914. The number
of cells and their percent viability were recorded at the beginning of
the experiment and after 3 days of treatment using exclusion
fluorochromes in a microcapillary cytometer. The difference between
the number of viable cells in vehicle-treated controls at 0 h and after
3 days of culture was considered to be 100%. The growth of the
treated groups is expressed as percentage of control a and d. For each
dose–response curve, the amount of drug needed to achieve 50%
growth inhibition (IC50) was calculated utilizing drug interaction
software b and e. Cell viability is shown in separate graphs (c and f).
Results are the average of three separate experiments
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panel). In SK-OV-3 cells, the kinetics of the cell cycle was
slightly different. Twenty-four, 48 or 72 h after treatment
with any of the compounds, the cells accumulated in G1
with a reduced proportion of cells still in S phase when
compared to vehicle-treated controls (Fig. 4a-c). After 96 h,
however, the three antiprogestins triggered accumulation of
Sub-G1 DNA particles when compared to the values at
72 h (Fig. 4d). The three compounds abrogated growth
along the study when compared to vehicle-treated controls
(Fig. 4e).
Lethal concentrations of antiprogestins induce
morphological and biochemical changes consistent,
at least in part, with apoptotic cell death
After culturing OV2008 or SK-OV-03 cells with 20 μM
antiprogestins, no lethality was observed; however, signs of
loss of viability were found at the 40 μM concentration
(Figs. 2c and f, 3a and b, and 4). Morphological studies
show that the number of OV2008 cells still adherent after
96 h treatment with 40 μM antiprogestins is minimal, yet
with differences among the treatments, with the effects
being those of RU-38486 > ORG-31710 > CDB-2914. The
majority of the cells at this point in time appear detached
and with morphological features similar to those shown by
cisplatin-treated cells (Fig. 5a). SK-OV-3, although less
sensitive to the lethal effects of the antiprogestins, show a
remarkably reduced number of still adherent cells after 96 h
treatment with a concomitant enhanced number of floating
cells with similar morphological features to those shown by
cisplatin-treated cells (Fig. 5b). Fragmentation of the DNA
was clearly observed after 60 h exposure to 40 μM RU-
38486 and ORG-31710 in OV2008 cells, whereas the effect
was less pronounced in CDB-2914-treated cells at the same
point in time (Fig. 5c, left panel). For SK-OV-3 cells,
treatment with 40 μM of the three compounds showed
DNA laddering upon 120 h incubation (Fig. 5c, right
panel).
To further explore the signaling molecules involved in
the lethal action of antiprogestins in ovarian cancer cells,
we treated OV2008 cells with 40 μM antiprogestins and
collected whole cell extracts after 24, 48 or 72 h
incubation. Results in Fig. 5d show that RU-38486
caused cleavage of the full-length caspase-3, 116 kDa
PARP substrate into the 86 kDa cleaved and inactive form
24 h after treatment, an effect that was more evident at
48 h, in association with down-regulation of cell cycle
Fig. 3 Effect of antiprogestins on cell cycle distribution in OV2008
cells.aLogarithmically growing OV2008 ovarian cancer cells were
exposed to 0, 20 or 40 μM RU-38486, ORG-31710 or CDB-2914 for
72 h. The percentage of cells with Sub-G1 DNA content (upper left),
or with DNA content consistent with G0-G1 (upper right), S (lower
left), and G2-M (lower right) phases of the cell cycle was determined
by microcapillary cytometric analysis after propidium iodide staining
of the DNA. b Logarithmically growing OV2008 cells were exposed
to DMSO (vehicle) or 40 μM antiprogestins for 12 h (upper left), 24 h
(upper right), or 48 h (lower left). The percentage of events consistent
with Sub-G1, G0-G1, S, and G2-M DNA content was analyzed after
propidium iodide staining utilizing microcapillary cytometry. The
number of cells was recorded at the beginning of the experiment and
after different periods of incubation with or without treatments (lower
right)
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cip1, and cleavage of
p27
kip1. RU-38486-induced lethality was associated with
down-regulation of the inhibitor of apoptosis protein
XIAP but, curiously, it occurred in the presence of high
levels of anti-apoptotic protein Bcl-2 when compared to
vehicle-treated controls. ORG-31710-induced cell death
associated with PARP cleavage and down-regulation of
Cdk-2, in the presence of high levels of Cdk inhibitors
p21
cip1 and p27
kip1. In contrast to RU-38486, ORG-
31710-induced cytotoxicity occurred with higher levels
o fX I A Pa n dn oc h a n g e si nB c l - 2w h e nc o m p a r e dt o
vehicle-treated controls. Finally, lethality associated to
CDB-2914 occurred with up-regulation and cleavage of
PARP, up-regulation of XIAP, and up-regulation and
cleavage of Bcl-2, in the presence of high levels of
p21
cip1 and p27
kip1. Altogether results in Fig. 5 suggest
that concentrations of antiprogestins higher than 20 μM
are lethal to p53-wild type OV2008 and p53-null SK-OV-
3; the molecular mediators of the cell death mechanisms,
as well as their interrelationship with cell cycle regulatory
proteins, differ among the antiprogestins and warrant
further investigations.
Cytostatic concentrations of antiprogestins increase
association of p21
cip1 and p27
kip1 with Cdk-2, promote
nuclear localization of p21
cip1 and p27
kip1, reduce nuclear
abundances of Cdk-2 and cyclin E, and inhibit the activity
of Cdk-2
In association with cyclin E, Cdk-2 is essential to drive the
cell cycle through the G1-S transition and into the S phase
whereas p21
cip1 and p27
kip1 are usually involved in
inhibiting cyclin E/Cdk-2 activity [29]. We questioned
whether the activity of Cdk-2 was related to the growth
inhibitory effect of the antiprogestins. OV2008 cells were
cultured for 12, 24, or 48 h in the presence of 20 μM RU-
38486, ORG-31710, or CDB-2914 (Fig. 6a). Twelve hours
after treatment with RU-38486, p21
cip1 levels increased
with respect to vehicle-treated controls. Such increase was
even higher 24 h later, and persisted 48 h following drug
exposure. Treatment with ORG-31710 also led to an
increase in p21
cip1 levels 12 h after exposure, a further
increase at 24 h, but it was followed by a decline at 48 h.
Finally, CDB-2914 induced a mild increase in p21
cip1 levels
at 12 h, followed by higher levels at 24 h and a further
Fig. 4 Effect of antiprogestins on cell cycle distribution in SK-OV-3
cells. Logarithmically growing SK-OV-3 cells were exposed to
DMSO (vehicle) or 40 μM RU-38486, ORG-31710 or CDB-2914
for 24 h a,4 8hb,7 2hc or 96 h d. The percentage of events
consistent with Sub-G1, G0-G1, S, and G2-M DNA content was
analyzed after propidium iodide staining utilizing microcapillary
cytometry. The number of cells was recorded at the beginning of the
experiment and after different periods of incubation with or without
treatments e
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observed for p27
cip1 with small differences. RU-38486
induced a slight increase in p27
kip1 levels at 12 h but a
larger increase at 24 and 48 h, whereas ORG-31710 needed
24 h exposure to increase p27
cip1, and CDB-2914 only
slightly increased p27
cip1 levels even after 48 h exposure.
No major modification in the total protein levels of Cdk-2
and cyclin E was observed in these experiments. When a
similar experiment was conducted in SK-OV-3 cells p21
cip1
and p27
kip1 increased in response to the antiprogestins as
well, but there was a pronounced decline in the abundance
of Cdk-2 not observed in OV2008 cells (Fig. S2).
Because nuclear localization of Cdk-2 is required for its
full activation and cell cycle progression [30, 31], we
analyzed whether the antiprogestins affect the nucleocyto-
plasmic trafficking of the Cdk inhibitors p21
cip1 and
p27
kip1, cyclin E and Cdk-2. OV2008 cells treated with
vehicle or 20 μM antiprogestins for 48 h were subjected to
subcellular fractionation and Western blot analysis. Results
in Fig. 6b reveal that the antiprogestins induced an increase
in nuclear localization of p21
cip1 and p27
kip1,w h i c h
correlated with decreased Cdk-2 and cyclin E nuclear
levels. As a consequence of the observed decrease in
Cdk-2 and cyclin E nuclear abundance, together with the
increase in the abundances of Cdk inhibitors, we asked
whether such changes were reflected in the modulation of
the activity of Cdk-2. We immunoprecipitated Cdk-2 from
vehicle-treated OV2008 cells or from OV2008 cells treated
with 20 μM antiprogestins for 48 h and did an in vitro
kinase assay using histone H1 as substrate. The results in
Fig. 6c show that the activity of Cdk-2 was inhibited in
both nucleus and cytoplasm, and such inhibition was
stronger when the cells were exposed to RU-38486 or
ORG-31710, whereas CDB-2914 caused the weakest
Fig. 5 Lethality of antiprogestins towards ovarian cancer cells.
OV2008 or SK-OV-3 cells were cultured in the presence of 40 μM
RU-38486, ORG-31710 or CDB-2914. After 60 h (OV2008) or 120 h
(SK-OV-3), floating cells were collected, adhered to a microscope
slide, stained with DAPI, and microscopic phase contrast and
fluorescence images were obtained from the same fields. As positive
control of apoptotic cell death, floating cells from cisplatin (CDDP)
treated cells were included in the morphological studies a and b.
Adherent untreated cells are also shown (CONTROL). Scale bar,
20 μm. c A similar experiment was done in which all floating and
attached cells were pelleted, total DNA was isolated, subjected to
agarose electrophoresis, stained with SYBR Gold nucleic acid stain,
and photographed with the Amersham Typhoon fluorescence imaging
system. A 100 base pair (bp) marker was run in parallel. (d) OV2008
cells were exposed to DMSO (Vehicle) or 40 μM RU-38486, ORG-
31710 or CDB-2914 for 72 h. Whole protein extracts were obtained
and separated by electrophoresis, and immunoblots were probed with
the indicated antibodies to recognize cell cycle and cell death related
proteins. The housekeeping gene GAPDH was used as protein loading
control
974 Invest New Drugs (2012) 30:967–980Fig. 6 Effect of antiprogestins on cell cycle regulatory proteins in
ovarian cancer cells. OV2008 cells were exposed to DMSO (Vehicle),
20 a-e or 40 μM d and e RU-38486, ORG-31710, or CDB-2914 for
the indicated times a, d, and e or 48 h b and c. a Whole protein
extracts (WCE) were obtained and separated by electrophoresis, and
immunoblots were probed with the indicated cell cycle related
antibodies. Whole protein extracts were also immunoprecipitated with
anti-Cdk-2 antibody and assayed for their capacity to phosphorylate
histone H1 in vitro in the presence of
32P ATP. b Isolation of nuclear
and cytosolic fractions was achieved, proteins from each fraction were
obtained and separated by electrophoresis, and immunoblots were
probed with the indicated antibodies. c Nuclear and cytosolic extracts
were imunoprecipitated with anti-Cdk-2 antibody, electrophoresed,
and probed with the indicated antibodies. The immunoprecipitates
were also assayed for their capacity to phosphorylate histone H1 in
vitro in the presence of
32P ATP. d Time-course experiment on the
effect of 20 or 40 μM antiprogestins on the expression of cell cycle-
related proteins. e Whole cell extracts from previous experiment were
imunoprecipitated with anti-Cdk-2 antibody, electrophoresed, probed
with the indicated antibodies, and also assayed for their capacity to
phosphorylate histone H1 in vitro. f A similar experiment was
performed as in d but instead of WCE, nuclear and cytoplasmic
protein extracts were isolated and immunoprecipitated with Cdk-2
antibody upon treatment of the cells with 20 or 40 μM antiprogestins
for 24 h
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cip1
and p27
kip1 that co-immunoprecipitated with Cdk-2, which
was more pronounced in the cytoplasm than in the nucleus,
suggesting that the inhibition in Cdk-2 activity is at least in
part likely due to an increase in the binding of the inhibitors
p21
cip1 and p27
kip1. The activity of Cdk-2 was also
remarkably inhibited in both nucleus and cytoplasm of SK-
OV-3 cells as shown when treated with RU-38486 (Fig. S3).
The magnitude of the increase in p21
cip1 and p27
kip1 and
the decline in Cdk-2 levels induced by the antiprogestins
was dose-dependent, with the particularity that the increase
in p21
cip1 occurred earlier than that of p27
kip1 (Fig. 6d).
When Cdk-2 was immunoprecipitated, there was a dose-
dependent increase in the amounts of p21
cip1 and p27
kip1
that co-immunoprecipitated with Cdk-2, which was associ-
ated with a parallel decline in the activity of Cdk-2
(Fig. 6e). A dose- and time-dependent inhibition of Cdk-2
activity was also observed in SK-OV-3 cells when exposed
to 20 or 40 μM ORG-31710 (Fig. S4).
In addition to the increased association of Cdk inhibitors
p21
cip1 and p27
kip1 to Cdk-2, another contributing factor for
the reduced Cdk-2 activity in response to antiprogestins
appears to be a decline in the nuclear levels of cyclin E
(Fig. 6b). To further confirm this assumption we immuno-
precipitated Cdk-2 from cytosolic and nuclear fractions of
OV2008 cells, which had been exposed for 24 h to 20 or
40 μM antiprogestins. Fig. 6f shows an evident dose-
dependent decline in Cdk-2 activity in both cellular
compartments, together with a major decline in cyclin E
nuclear levels, and cyclin E redistribution to the cytoplasm,
where lower molecular weight cyclin E fragments were also
observed. The association of p21
cip1 and p27
kip1 to Cdk-2
in the cytoplasmic fraction correlated with the decline in the
activity of Cdk-2 in this cellular compartment even in the
presence of cyclin E, which however may be undergoing
accelerated proteasomal degradation. In the nuclear frac-
tion, however, the correlation among binding of Cdk
inhibitors to Cdk-2 and decline in Cdk-2 activity is not
apparent, suggesting that it may be the lack of cyclin E
rather than the increase in Cdk inhibitors the main cause for
the blunted activity of Cdk-2 in the nucleus.
The dose-dependent decline in Cdk-2 activity observed
in OV2008 cells (Fig. 6e and f), and SK-OV-3 (Fig. S4),
correlated with a dose-dependent growth inhibitory effect
elicited by the antiprogestins (Fig. 2 and Fig. S5).
Altogether these results suggest that the dose-dependent
antiprogestin-mediated inhibition of growth in ovarian
cancer cells involves increased nuclear abundance of the
Cdk inhibitors p21
cip1 and p27
kip2, decreased Cdk-2 and
cyclin E nuclear levels, redistribution of cyclin E to the
cytoplasm, and a remarkable decline in the activity of the
cell cycle regulatory protein Cdk-2 in both nuclear and
cytoplasmic compartments.
Discussion
Ovarian cancer is known as a silent killer due to its late
detection and high mortality. Despite countless efforts to
develop early diagnostic tools and new treatment
approaches, the 5-year survival for these patients has only
improved from 37% to 45% in the past 30 years [32]. To
cure this disease efforts are geared to chemoprevention and
assessment of risk factors, early detection biomarkers,
identification of early disease symptoms, and development
of targeted drugs to accompany standard therapy [33].
However, since screening strategies for early diagnosis
have so far failed and most patients still die from the
disease, new therapeutic options are desperately needed.
The results presented in this work clearly show that three
different antiprogestin compounds are cytotoxic to ovarian
cancer cells displaying two main effects: (i) a cytostatic
effect at lower concentrations blocking cell growth at the
G1 phase of the cell cycle; and (ii) a lethal effect at higher
doses associated with morphological features of apoptosis
and fragmentation of the genomic DNA. The overall
toxicity of antiprogestins involved a dose-dependent de-
cline in the activity of the cell cycle regulatory protein Cdk-
2 (Fig. 7).
Cdk-2 has been shown to be critical in promoting the
transition of cells in the cell cycle from G1 to S phase [29].
For instance, cyclin E/Cdk-2 is needed for the stimulation
of histone gene transcription [34], which is one of the major
events that mark the entry into the S phase. To drive cell
cycle progression, Cdk-2 should be free of p21
cip1 and
p27
kip1 binding [29], bound to cyclin E, and allocated to the
nucleus to phosphorylate cell cycle regulatory proteins [31,
35]. We show that antiprogestins affect the nucleocytoplas-
mic trafficking of Cdk inhibitors p21
cip1 and p27
kip1, Cdk-2
and its co-factor cyclin E. We demonstrate that antiproges-
tins increase p21
cip1 and p27
kip1 abundances in both
cytoplasm and nuclear compartments, which correlate with
decreased Cdk-2 and cyclin E nuclear levels, increased
cytoplasmic cyclin E and a remarkable decline in the
activity of Cdk-2 in both subcellular compartments. The
magnitude of inhibition of Cdk-2 activity was related to the
growth inhibition potency of the compounds with RU-
38486 > ORG-31710 > CDB-2914. Supporting our results,
a decline in cyclin E-associated kinase activity (presumably
Cdk-2) has been previously reported for T-47D breast
cancer cells in response to ORG-31710 in the absence of
significant changes in cyclin E and Cdk levels, but in the
presence of elevated concentrations of p21
cip1, suggesting
that p21
cip1 contributes to the reduction in Cdk-2 activity
after antiprogestin treatment [9]. In ovarian cancer cells we
show that not only the increased association of p21
cip1 and
p27
kip1 to Cdk-2 may account for the reduced Cdk-2
activity in the nucleus in response to antiprogestins, but
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redistribution of cyclin E to the cytoplasm, are related
variables leading to blunting Cdk-2 nuclear activity
needed for G1 to S transition. A recent study using
LNCaP prostate cancer cells revealed that targeting Cdk-
2 to the nucleus is sufficient to prevent growth inhibition
t r i g g e r e db y1 , 2 5( O H ) 2 D3 [36], suggesting that
antiprogestin-mediated growth inhibition and growth
arrest triggered by metabolites of vitamin D may share
common molecular intermediaries.
Because Cdk-2 is frequently up-regulated in ovarian
tumors [37], the potent inhibition of Cdk-2 elicited by
antiprogestins may be critically important from a transla-
tional therapeutics viewpoint. Moreover, because cytoplas-
mic localization of Cdk inhibitor p27
kip1 in ovarian cancer
patients has been associated with poor prognosis [38], by
promoting an increase in p27
kip1 in the nucleus, antipro-
gestins may be able to rescue the tight inhibitory control of
Cdk inhibitors on Cdk-2 activity which is frequently lost in
ovarian cancer. One question that deserves an answer is
whether p21
cip1 and/or p27
kip1 that accumulate after
antiprogestin exposure are required for antiprogestin-
mediated Cdk-2 inhibition and/or cell cycle arrest, or
whether it is the decline in nuclear cyclin E levels itself
sufficient to cause the reduction in nuclear Cdk-2 activity.
In support of the latter hypothesis overexpression of cyclin
E in LNCaP prostate cancer cells blocked 1, 25 (OH) 2 D3-
mediated growth inhibition, Cdk-2 relocalization to the
cytoplasm, and inhibition of Cdk-2 activity [36], suggesting
that a similar mechanism may be taking place in ovarian
cancer cells upon antiprogestin treatment. Because in
mammalian cells cyclin E is degraded in an ubiquitin- and
proteasome-dependent pathway [39, 40], it is possible that
by causing cyclin E redistribution to the cytoplasm
antiprogestins promote cyclin E proteasomal degradation.
This pharmacologic engagement of the proteasome system
degrading G1 cyclins such as D1 and E has been previously
proposed as a molecular target for cancer therapy [41].
A potential target of antiprogestin action is the ubiquitin-
proteasome system (UPS). This idea is based on the
following facts: (i) to transition from G1 to S phase and
to commit to DNA synthesis, the cells must degrade the
Cdk-2 inhibitors p27
kip1 and p21
cip via the Skp1-Cullin-F-
box protein/Skp2 (SCF
Skp2) E3 ubiquitin ligase complex
[42, 43]. This requires the Cdk-2-dependent phosphoryla-
tion of p27
kip1 on Thr187 [42] and p21
cip1 on Ser130 [43];
(ii) antiprogestins have a du a le f f e c tb l o c k i n gC d k - 2
activity and triggering the accumulation of p21
cip1 and
p27
kip1, and these Cdk-2 inhibitors rely on the UPS for their
disappearance to enforce the orderly progression of the cell
cycle from G1 to the S phase; (iii) finally, there are
remarkable similarities in the behavior of antiprogestins and
proteasome inhibitors in inducing p21
cip1 and p27
kip1
accumulation before triggering caspase-associated lethality
[18, 19, 44]. It is therefore possible that antiprogestins
induce G1 growth arrest by interfering with the
proteasome-mediated degradation of p27
kip1/p21
cip1, lead-
ing to Cdk-2 inhibition. It is also feasible that the sustained
levels of p27
kip and p21
cip1 in response to cytostatic doses
of antiprogestins are the consequence of a reduced
recognition of the Cdk inhibitors by the UPS. Because
ovarian cancer cells function with high activity of the UPS
[44], this proteolytic machinery may be degrading Cdk
inhibitors at a high rate, causing the reduced basal levels we
found in ovarian cancer cells, thus favoring their prolifer-
ation. Antiprogestins may mitigate this process.
In addition to regulating cell cycle progression, Cdk-2 is
involved in cell survival after DNA damage and in DNA
repair pathways [45, 46]. As a survival factor, for instance,
Cdk-2 phosphorylates the FOXO1 transcription activator of
Fig. 7 Proposed model for the cytotoxic effect of antiprogestins in
ovarian cancer cells. a In normal growing conditions or in the
presence of very low doses of antiprogestins, the activity of Cdk-2 is
elevated and the cell cycle progresses. At certain threshold of
antiprogestin levels, the activity of Cdk-2 is reduced in association
with cytostasis. At higher doses of antiprogestins, Cdk-2 activity is
blunted leading to cell death. b Antiprogestins reduce nuclear and
cytoplasmic activity of Cdk-2 in association with up-regulation of
Cdk-2 inhibitors p21
cip1 (p21) and p27
kip1 (p27), down-regulation of
Cdk-2 and cyclin E in the nucleus, and cyclin E redistribution to the
cytoplasm where it may undergo accelerated proteasome degradation.
The inhibition of nuclear activity of Cdk-2 leads to G1 cell cycle arrest
due to abrogation of Cdk-2 driven pathways needed for DNA
duplication and S phase progression. The inhibition of cytoplasmic
Cdk-2 activity, when bypassing certain minimal activity threshold,
ultimately leads to cell death likely due to abrogation of a Cdk-2
dependent cell survival pathway
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47] . If the activity of Cdk-2 is abolished by an
antiprogestin, then FOXO1 may not be retained in the
cytoplasm, consequently migrating to the nucleus where it
promotes the expression of pro-apoptotic genes [45, 47].
The lethality of high concentration antiprogestins associated
with features of apoptosis as compared to platinum-
induced lethality in the same cell lines in terms of
nuclear and DNA fragmentation. However, the molecular
mediators of antiprogestin-mediated cell death varied
among the steroids. Although cleavage of the caspase-3
substrate PARP was a commonality among RU-38486,
ORG-31710 and CDB-2914, the latter also caused an up-
regulation of PARP which was also previously observed
in cultured human uterine leiomyoma cells [24]. In
addition, CDB-2914 caused up-regulation of the anti-
apoptotic proteins XIAP and Bcl-2, yet cell death still
ensued but with less effectiveness than that observed after
exposure to high concentrations of RU-38486 or ORG-
31710 in which both XIAP and Bcl-2 are down-regulated
after 3 days of treatment. Thus, the extended up-regulation
of XIAP and Bcl-2 upon CDB-2914 treatment but not
after RU-38486 or ORG-31710 may account for the
reduced cytotoxic potency of CDB-2914. Although with
different potencies, high concentrations of antiprogestins
were able to lead the cells to crossing a cell death threshold or
point of no return in which the pro-apoptotic load of the cell
surpasses its anti-apoptotic buffering capacity.
Apoptosis induced by antiprogestins has also been
reported in cultured human periovulatory granulosa cells
in which RU-38486 and ORG-31710 caused an increase
in the activity of executer caspase-3 and fragmentation of
the DNA [26]. RU-38486 was also shown to cause
apoptosis in breast, cervical, endometrial, and prostate
cancer cells in association with activation of caspase-3,
down-regulation of Bcl-2 and secretion of TGFβ1[ 14, 48,
49]. Using ovarian cancer cell lines, our work expanded to
CDB-2914 the previously reported cytotoxicity of RU-
38486 and ORG-31710.
It is unknown whether antiprogestins inhibit cell growth
involving progesterone receptors (PR), glucocorticoid
receptors (GR) or neither one of them. In fact it has been
previously suggested a dissociation between the anti-
hormone and anti-proliferative activity of antiprogestins
[50]. This is further supported by studies in MDA-MB-231
breast cancer cells lacking both ER and PR, in which RU-
38486 retained its antiproliferative activity [14]. On the
other hand, our laboratory using SK-OV-3 cells [18] and
others using SV-40 transformed ovarian cystadenoma cells
[51] have shown that RU-38486 elicits progesterone-like
effects in terms of growth inhibition although with greater
potency than progesterone, whereas others [52] using HOC-
7 ovarian carcinoma cells demonstrated that high concen-
tration (30 μM) progesterone stimulates p21
cip1 and p27
kip1
expression and inhibit Cdk-2 activity mimicking our
observations with antiprogestins. Whether progesterone
and antiprogestins share similar mechanism of action when
acting as anti-proliferative agents, and which are their
downstream targets, need to be investigated to identify the
genetic background of ovarian cancers required for suscep-
tibility to growth inhibition by antiprogestins.
In summary, the results from the present work provide
evidence suggesting that antiprogestins originally utilized
for reproductive medicine can be repurposed or reposi-
tioned for another modality-of-use, their anti-ovarian cancer
property, which involves their capacity to ablate the activity
of the cell cycle regulatory protein Cdk2.
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